Clinical Trials Logo

Acute Myeloid Leukemia clinical trials

View clinical trials related to Acute Myeloid Leukemia.

Filter by:

NCT ID: NCT04745676 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

A Telehealth Advance Care Planning Intervention for Older Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Start date: March 25, 2021
Phase: N/A
Study type: Interventional

This is a pilot study to evaluate the usability and feasibility of a telehealth-delivered advance care planning intervention among 20 older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), their caregivers, and oncologists.

NCT ID: NCT04742101 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia

Start date: March 10, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the safety, tolerability and clinical activity of the combination S65487 with azacitidine in patients with acute myeloid leukaemia.

NCT ID: NCT04730258 Recruiting - Clinical trials for Acute Myeloid Leukemia

A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML

TWT-202
Start date: April 16, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to test the safety of an investigational drug called CFI-400945 alone and in combination with azacitidine.

NCT ID: NCT04726241 Recruiting - Clinical trials for Acute Myeloid Leukemia

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Start date: April 18, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.

NCT ID: NCT04722952 Recruiting - Clinical trials for Acute Myeloid Leukemia

PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine,Cytarabine, G-CSF for Refractory or Relapsed AML

Start date: May 1, 2021
Phase: Phase 3
Study type: Interventional

This is an single center, single arm, phase 3 study to evaluate efficacy and safety of PD-1 Inhibitor combined with DNA methyltransferase inhibitor Azacytidine and HAG regimen for patients with relapsed and refractory acute myeloid leukemia.

NCT ID: NCT04714372 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia

Start date: November 3, 2021
Phase: Phase 1
Study type: Interventional

This Phase I open-label dose escalation study is conducted in two stages with a primary endpoint to identify the maximum tolerated dose (MTD) of FT538 when administered with daratumumab in patients 12 years and older with advanced acute myeloid leukemia (AML) and related myeloid diseases.

NCT ID: NCT04708444 Not yet recruiting - Clinical trials for Acute Myeloid Leukemia

Prognostic Value of CD318 in AML at Assiut University Hospital.

Start date: March 2021
Phase:
Study type: Observational

We will focus on the prognostic value of CD318 in acute myeloid leukemia patients at Assiut University Hospital

NCT ID: NCT04708054 Recruiting - Clinical trials for Acute Myeloid Leukemia

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

Start date: October 21, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effect of venetoclax together with busulfan, cladribine, and fludarabine in treating patients with high-risk acute myeloid leukemia or myelodysplastic syndrome who are undergoing stem cell transplant. Chemotherapy drugs, such as venetoclax, busulfan, cladribine, and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding venetoclax to the current standard of care stem cell transplant regimen of busulfan, fludarabine, and cladribine may help to control high-risk acute myeloid leukemia or myelodysplastic syndrome.

NCT ID: NCT04692948 Recruiting - Clinical trials for Acute Myeloid Leukemia

TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia

Start date: December 9, 2019
Phase: N/A
Study type: Interventional

This is a clinical study of TAA6 cell injection in the treatment of patients with relapsed / refractory Acute Myeloid Leukemia . The purpose is to evaluate the safety and effectiveness of CD276 targeted autologous chimeric antigen receptor T cells infusion in patients with relapsed / refractory CD276 positive Acute Myeloid Leukemia.(TAA6 cell injection is a T cell targeting CD276 chimeric antigen receptor)

NCT ID: NCT04679285 Recruiting - Clinical trials for Acute Myeloid Leukemia

Minimal Residual Disease Evaluation on Cryopreserved Ovarian Fragments in Younger Patients Treated for Acute Myeloid Leukemia

FERTILAM
Start date: April 26, 2021
Phase:
Study type: Observational

Cryopreservation of ovarian cortex represents an option for fertility preservation in patients diagnosed with acute myeloid leukemia and requiring allogeneic stem cell transplantation. This pilot study aims to evaluate the minimal residual disease on ovarian fragments harvested before allogeneic stem cell transplantation at the time of complete remission.